RVU120 with everolimus in children whose medulloblastoma has returned or is growing
Tests RVU120 alone and with everolimus in children with recurring medulloblastoma.
Key facts
- Who runs it
- Instytut Pomnik Centrum Zdrowia Dziecka
- Where
- Warsaw, PolandSee the site
- Trial code
- Registry title
- Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 48 people, planned
- Started
- 31 Jul 2026
- Expected to end
- 30 Sept 2031
- Type of study
- Interventional
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers whose Group 3 or Group 4 medulloblastoma has come back or is getting worse after first standard treatment.
- Age
- 3 years to 18 years (the record also lists a maximum age of 17 years)
- Sex
- All sexes can join.
- Disease stage
- Group 3 or Group 4 medulloblastoma that has come back or is getting worse after first standard treatment. The group must be confirmed by a methylation test. Children with spread (metastatic) disease can join.
- Earlier treatment
- Must have recovered from the acute side effects (grade 1 or lower) of earlier chemotherapy, immunotherapy or radiotherapy. Must not have had a CDK8 inhibitor or an mTOR inhibitor such as everolimus, sirolimus or temsirolimus.
- Biomarker or test result
- Medulloblastoma group (Group 3 or Group 4) confirmed by CLIA-certified methylation testing, at diagnosis or at recurrence.
Main reasons for not taking part
- Pregnant or breastfeeding
- Serious unrelated illness that could make the treatment unsafe
- Major surgery, including tumour biopsy, within 14 days before joining
- Poor absorption of medicines from the gut, or major bowel or stomach surgery
- Earlier treatment with a CDK8 inhibitor or an mTOR inhibitor
Where in Poland
- Instytut Pomnik Centrum Zdrowia DzieckaWarsaw, PolandNot yet recruiting
About the trial
What the trial wants to find out
1. To evaluate the safety and toxicity of RVU120 as a single agent and combined with everolimus when administered to children with recurrent or progressive G3 or G4 medulloblastoma 2. To determine the MTD and/or RP2D of RVU120 as a single agent and in combination with everolimus in children with recurrent or progressive G3 or G4 medulloblastoma.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
- Plain-language title
- RVU120 with everolimus in children whose medulloblastoma has returned or is growingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 October 2026